ArticleFrontiers in pharmacology2024

A real-world experience of venetoclax combined with hypomethylating agents vs. monotherapy hypomethylating agents in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia patients.

Ludan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.